Nygen is revolutionizing biological data analysis, empowering biologists to become computational experts. Our scalable platform bridges computational biology and experimental research, democratizing analytics access across biopharma, biotech, and academia. We accelerate drug discovery and therapeutic development by addressing the expanding single-cell data landscape, crucial for solving complex biological challenges.
Our breakthrough technology transforms single-cell data into actionable drug targets. With Nygen Analytics for data analysis, Nygen Database for data storage, and LLM-augmented Nygen Insights for interpretation, we aim to evolve into an autonomous discovery engine, enabling researchers to maximize data value and drive drug development.
Nygen's platform leverages breakthrough infrastructure enabling a new paradigm of agent-driven data analytics.
Designed for low-cost, high-volume analytics with industry-leading 5% cost of goods sold.
AI models deployed in data context for deep cell characterization, literature validation and biomarker discovery.
The only platform in the market with these security standards.
Spread across 20 worldwide server locations.
Proprietary machine learning technologies designed to generate cutting-edge cell atlases encompassing billions of cells.
Looking ahead, Nygen is committed to developing out-of-distribution prediction capabilities for perturbation and disease effects, positioning ourselves as the leading autonomous discovery engine in biological research.
Headquartered in Medicon Village, Lund, Sweden, Nygen operates from one of Europe's most dynamic biopharma innovation hubs. Medicon Village serves as a catalyst for life science breakthroughs, bringing together leading research institutions, biotech companies, and pharmaceutical giants. This strategic location positions us at the heart of Scandinavian biotech excellence, fostering collaborations that drive scientific progress and innovation.
Our founding team combines deep expertise in computational biology and single-cell omics, with PhDs and over 25 years of experience building software and technology for life sciences.
Computational Biologist with published papers garnering 100+ citations and GitHub repositories with 100+ stars in the single-cell space.
Single-cell Scientist (Associate Professor) who established the first single-cell facility in Sweden, secured grants over €3M in academic positions, and initiated clinical trials based on single-cell data.
Single-cell profiling pioneer and serial founder of product and service-based companies in genomics.
Cybersecurity startup founder whose company was acquired by a Fortune 100 company. Active as Angel/VC/LP investor.
